Inducible glutamate oxaloacetate transaminase as a therapeutic target against ischemic stroke

Antioxidants and Redox Signaling

Volumn 22, Issue 2, 2015, Pages 175-186

  Khanna, Savita ^a   Briggs, Zachary ^a   Rink, Cameron ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; GLUTAMIC ACID; NEUROTOXIN;

BRAIN ISCHEMIA; BRAIN LEVEL; BRAIN METABOLISM; CELL SURVIVAL; CITRIC ACID CYCLE; ENERGY; ENZYME ACTIVITY; EXCITOTOXICITY; GLUCOSE BRAIN LEVEL; HUMAN; NERVE CELL; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SURVIVAL FACTOR; ANIMAL; CEREBROVASCULAR ACCIDENT; ENZYMOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; ASPARTATE AMINOTRANSFERASES; CITRIC ACID CYCLE; GLUTAMIC ACID; HUMANS; STROKE;

EID: 84920197989     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.6106     Document Type: Review

References (99)

1. Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, MacDonald JF, and Tymianski M. A key role for TRPM7 channels in anoxic neuronal death. Cell 115: 863-877, 2003.
2. Aarts MM and Tymianski M. TRPMs and neuronal cell death. Pflugers Arch 451: 243-249, 2005.
3. Anderson DC, Bottini AG, Jagiella WM, Westphal B, Ford S, Rockswold GL, and Loewenson RB. A pilot study of hyperbaric oxygen in the treatment of human stroke. Stroke 22: 1137-1142, 1991.
4. Araque A, Parpura V, Sanzgiri RP, and Haydon PG. Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci 22: 208-215, 1999.
5. Auer RN, Coupland SG, Jason GW, Archer DP, Payne J, Belzberg AJ, Ohtaki M, and Tranmer BI. Postischemic therapy with MK-801 (dizocilpine) in a primate model of transient focal brain ischemia. Mol Chem Neuropathol 29: 193-210, 1996.
6. Balcar VJ and Johnston GA. The structural specificity of the high affinity uptake of L-glutamate and L-aspartate by rat brain slices. J Neurochem 19: 2657-2666, 1972.
7. Banjac A, Perisic T, Sato H, Seiler A, Bannai S, Weiss N, Kolle P, Tschoep K, Issels RD, Daniel PT, Conrad M, and Bornkamm GW. The cystine/cysteine cycle: a redox cycle regulating susceptibility versus resistance to cell death. Oncogene 27: 1618-1628, 2008.
8. Bano D and Nicotera P. Ca2 + signals and neuronal death in brain ischemia. Stroke 38: 674-676, 2007.
9. Bano D, Young KW, Guerin CJ, Lefeuvre R, Rothwell NJ, Naldini L, Rizzuto R, Carafoli E, and Nicotera P. Cleavage of the plasma membrane Na +/Ca2 + exchanger in excitotoxicity. Cell 120: 275-285, 2005.
10. Benarroch EE. Glycogen metabolism: metabolic coupling between astrocytes and neurons. Neurology 74: 919-923, 2010.
11. Benjamin AM and Quastel JH. Locations of amino acids in brain slices from the rat. Tetrodotoxin-sensitive release of amino acids. Biochem J 128: 631-646, 1972.
12. Besancon E, Guo S, Lok J, Tymianski M, and Lo EH. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol Sci 29: 268-275, 2008.
13. Britton P, Lu XC, Laskosky MS, and Tortella FC. Dextromethorphan protects against cerebral injury following transient, but not permanent, focal ischemia in rats. Life Sci 60: 1729-1740, 1997.
14. Bruno V, Battaglia G, Copani A, D'OnofrioM, Di Iorio P, De Blasi A, Melchiorri D'Flor PJ, and Nicoletti F. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21: 1013-1033, 2001.
15. Buchan AM, Lesiuk H, Barnes KA, Li H, Huang ZG, Smith KE, and Xue D. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke 24: I148-I152, 1993.
16. Campos F, Sobrino T, Ramos-Cabrer P, Argibay B, Agulla J, Perez-Mato M, Rodriguez-Gonzalez R, Brea D, and Castillo J. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab 31: 1378-1386, 2011.
17. Campos F, Sobrino T, Ramos-Cabrer P, and Castillo J. Oxaloacetate: a novel neuroprotective for acute ischemic stroke. Int J Biochem Cell Biol 44: 262-265, 2012.
18. Chen J, Graham SH, and Simon RP. A comparison of the effects of a sodium channel blocker and an NMDA antagonist upon extracellular glutamate in rat focal cerebral ischemia. Brain Res 699: 121-124, 1995.
19. Cheng YD, Al-Khoury L, and Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 1: 36-45, 2004.
20. Chu K, Lee ST, Sinn DI, Ko SY, Kim EH, Kim JM, Kim SJ, Park DK, Jung KH, Song EC, Lee SK, Kim M, and Roh JK. Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke 38: 177-182, 2007.
21. Cudennec A, Duverger D, Benavides J, Scatton B, and Nowicki JP. Effect of eliprodil, an NMDA receptor antagonist acting at the polyamine modulatory site, on local cerebral glucose use in the rat in the rat brain. Brain Res 664: 41-48, 1994.
22. Curtis DR, Phillis JW, and Watkins JC. Chemical excitation of spinal neurones. Nature 183: 611-612, 1959.
23. Danbolt NC, Storm-Mathisen J, and Kanner BI. An [Na + +K+[coupled L-glutamate transporter purified from rat brain is located in glial cell processes. Neuroscience 51: 295-310, 1992.
24. Danton GH and Dietrich WD. The search for neuroprotective strategies in stroke. AJNR Am J Neuroradiol 25: 181-194, 2004.
25. Davis SM, Albers GW, Diener HC, Lees KR, and Norris J. Termination of acute stroke studies involving selfotel treatment. ASSIST steering committed. Lancet 349: 32, 1997.
26. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, and Norris J. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31: 347-354, 2000.
27. De Keyser J, Sulter G, and Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci 22: 535-540, 1999.
28. Domercq M, Sanchez-Gomez MV, Sherwin C, Etxebarria E, Fern R, and Matute C. System xc-and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. J Immunol 178: 6549-6556, 2007.
29. Evans RH, Francis AA, Hunt K, Oakes DJ, and Watkins JC. Antagonism of excitatory amino acid-induced responses and of synaptic excitation in the isolated spinal cord of the frog. Br J Pharmacol 67: 591-603, 1979.
30. Gerencser AA, Mark KA, Hubbard AE, Divakaruni AS, Mehrabian Z, Nicholls DG, and Polster BM. Real-time visualization of cytoplasmic calpain activation and calcium deregulation in acute glutamate excitotoxicity. J Neurochem 110: 990-1004, 2009.
31. Gladstone DJ, Black SE, and Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33: 2123-2136, 2002.
32. Gottlieb M, Wang Y, and Teichberg VI. Blood-mediated scavenging of cerebrospinal fluid glutamate. J Neurochem 87: 119-126, 2003.
33. Gribkoff VK, Starrett JE, Jr., Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, Frantz SW, Heman K, Hibbard JR, Huston K, Johnson G, Krishnan BS, Kinney GG, Lombardo LA, Meanwell NA, Molinoff PB, Myers RA, Moon SL, Ortiz A, Pajor L, Pieschl RL, Post-Munson DJ, Signor LJ, Srinivas N, Taber MT, Thalody G, Trojnacki JT, Wiener H, Yeleswaram K, and Yeola SW. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med 7: 471-477, 2001.
34. Haslam RJ and Krebs HA. The metabolism of glutamate in homogenates and slices of brain cortex. Biochem J 88: 566-578, 1963.
35. Hayashi T. Effects of sodium glutamate on the nervous system. Keio J Med 3:192-193, 1954.
36. Hollmann M, O'Shea-Greenfield A, Rogers SW, and Heinemann S. Cloning by functional expression of a member of the glutamate receptor family. Nature 342: 643-648, 1989.
37. Horn J and Limburg M. Calcium antagonists for ischemic stroke: a systematic review. Stroke 32: 570-576, 2001.
38. Hoyte L, Barber PA, Buchan AM, and Hill MD. The rise and fall of NMDA antagonists for ischemic stroke. Curr Mol Med 4: 131-136, 2004.
39. Jensen BS. BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Rev 8: 353-360, 2002.
40. Kawasaki-Yatsugi S, Yatsugi S, Takahashi M, Toya T, Ichiki C, Shimizu-Sasamata M, Yamaguchi T, and Minematsu K. A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats. Brain Res 793: 39-46, 1998.
41. Ketheeswaranathan P, Turner NA, Spary EJ, Batten TF, McColl BW, and Saha S. Changes in glutamate transporter expression in mouse forebrain areas following focal ischemia. Brain Res 1418: 93-103, 2011.
42. Khanna S, Roy S, Ryu H, Bahadduri P, Swaan PW, Ratan RR, and Sen CK. Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J Biol Chem 278: 43508-43515, 2003.
43. Kohara A, Takahashi M, Yatsugi S, Tamura S, Shitaka Y, Hayashibe S, Kawabata S, and Okada M. Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models. Brain Res 1191: 168-179, 2008.
44. Kong Q, Chang LC, Takahashi K, Liu Q, Schulte DA, Lai L, Ibabao B, Lin Y, Stouffer N, Das Mukhopadhyay C, Xing X, Seyb KI, Cuny GD, Glicksman MA, and Lin CL. Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J Clin Invest 124: 1255-1267, 2014.
45. Kostandy BB. The role of glutamate in neuronal ischemic injury: the role of spark in fire. Neurol Sci 33: 223-237, 2012.
46. Krebs HA. Metabolism of amino-acids: deamination of amino-acids. Biochem J 29: 1620-1644, 1935.
47. Kristian T and Siesjo BK. Calcium in ischemic cell death. Stroke 29: 705-718, 1998.
48. Leach MJ, Swan JH, Eisenthal D, Dopson M, and Nobbs M. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 24: 1063-1067, 1993.
49. Lekieffre D, Benavides J, Scatton B, and Nowicki JP. Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model. Brain Res 776: 88-95, 1997.
50. Liebeskind DS and Kasner SE. Neuroprotection for ischaemic stroke: an unattainable goal? CNS Drugs 15: 165-174, 2001.
51. Lucas DR and Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol 58: 193-201, 1957.
52. Mui K, Yoo AJ, Verduzco L, Copen WA, Hirsch JA, Gonzalez RG, and Schaefer PW. Cerebral blood flow thresholds for tissue infarction in patients with acute ischemic stroke treated with intra-arterial revascularization therapy depend on timing of reperfusion. AJNR Am J Neuroradiol 32: 846-851, 2011.
53. Muir KW, Holzapfel L, and Lees KR. Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke. Cerebrovasc Dis 10: 431-436, 2000.
54. Murphy TH, Schnaar RL, and Coyle JT. Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 4: 1624-1633, 1990.
55. Nagy D, Marosi M, Kis Z, Farkas T, Rakos G, Vecsei L, Teichberg VI, and Toldi J. Oxaloacetate decreases the infarct size and attenuates the reduction in evoked responses after photothrombotic focal ischemia in the rat cortex. Cell Mol Neurobiol 29: 827-835, 2009.
56. Naito S and Ueda T. Adenosine triphosphate-dependent uptake of glutamate into protein I-associated synaptic vesicles. J Biol Chem 258: 696-699, 1983.
57. Nawy S and Jahr CE. Suppression by glutamate of cGMPactivated conductance in retinal bipolar cells. Nature 346: 269-271, 1990.
58. Nighoghossian N, Trouillas P, Adeleine P, and Salord F. Hyperbaric oxygen in the treatment of acute ischemic stroke. A double-blind pilot study. Stroke 26: 1369-1372, 1995.
59. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, and Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol 59: 467-477, 2006.
60. Occhiuto F, Zangla G, Samperi S, Palumbo DR, Pino A, De Pasquale R, and Circosta C. The phytoestrogenic isoflavones from Trifolium pratense L. (Red clover) protects human cortical neurons from glutamate toxicity. Phytomedicine 15: 676-682, 2008.
61. Olverman HJ, Jones AW, and Watkins JC. L-glutamate has higher affinity than other amino acids for [3H]-D-AP5 binding sites in rat brain membranes. Nature 307: 460-462, 1984.
62. Pardridge WM and Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the bloodbrain barrier. Methods Enzymol 503: 269-292, 2012.
63. Patel V, Rink C, Gordillo GM, Khanna S, Gnyawali U, Roy S, Shneker B, Ganesh K, Phillips G, More JL, Sarkar A, Kirkpatrick R, Elkhammas EA, Klatte E, Miller M, Firstenberg MS, Chiocca EA, Nesaretnam K, and Sen CK. Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr 142: 513-519, 2012.
64. Perez-Mato M, Ramos-Cabrer P, Sobrino T, Blanco M, Ruban A, Mirelman D, Menendez P, Castillo J, and Campos F. Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. Cell Death Dis 5: e992, 2014.
65. Porasuphatana S, Tsai P, and Rosen GM. The generation of free radicals by nitric oxide synthase. Comp Biochem Physiol C Toxicol Pharmacol 134: 281-289, 2003.
66. Radermacher KA, Wingler K, Kleikers P, Altenhofer S, Hermans J, Jr., Kleinschnitz C, and Hhw Schmidt H. The 1027th target candidate in stroke: will NADPH oxidase hold up? Exp Transl Stroke Med 4: 11, 2012.
67. Rao VL, Dogan A, Bowen KK, Todd KG, and Dempsey RJ. Antisense knockdown of the glial glutamate transporter GLT-1 exacerbates hippocampal neuronal damage following traumatic injury to rat brain. Eur J Neurosci 13: 119-128, 2001.
68. Rink C, Christoforidis G, Abduljalil A, Kontzialis M, Bergdall V, Roy S, Khanna S, Slivka A, Knopp M, and Sen CK. Minimally invasive neuroradiologic model of preclinical transient middle cerebral artery occlusion in canines. Proc Natl Acad Sci USA 105: 14100-14105, 2008.
69. Rink C, Christoforidis G, Khanna S, Peterson L, Patel Y, Abduljalil A, Irfanoglu O, Machiraju R, Bergdall VK, and Sen CK. Tocotrienol vitamin E protects against preclinical canine ischemic stroke by inducing arteriogenesis. J Cereb Blood Flow Metab 31: 2218-2230, 2011.
70. Rink C, Gnyawali S, Heigel M, Roy S, Sen CK, and Khanna S. Inducible glutamate oxaloacetate transaminase: a new target for stroke therapy. Stroke 45: AWP216-AWP216, 2014.
71. Rink C, Gnyawali S, Peterson L, and Khanna S. Oxygeninducible glutamate oxaloacetate transaminase as protective switch transforming neurotoxic glutamate to metabolic fuel during acute ischemic stroke. Antioxid Redox Signal 14: 1777-1785, 2011.
72. Rink C and Khanna S. Significance of brain tissue oxygenation and the arachidonic acid cascade in stroke. Antioxid Redox Signal 14: 1889-1903, 2011.
73. Rink C, Roy S, Khan M, Ananth P, Kuppusamy P, Sen CK, and Khanna S. Oxygen-sensitive outcomes and gene expression in acute ischemic stroke. J Cereb Blood Flow Metab 30: 1275-1287, 2010.
74. Rothman SM and Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 19: 105-111, 1986.
75. Rusyniak DE, Kirk MA, May JD, Kao LW, Brizendine EJ, Welch JL, Cordell WH, and Alonso RJ. Hyperbaric oxygen therapy in acute ischemic stroke: results of the hyperbaric oxygen in acute ischemic stroke trial pilot study. Stroke 34: 571-574, 2003.
76. Santos MS, Moreno AJ, and Carvalho AP. Relationships between ATP depletion, membrane potential, and the release of neurotransmitters in rat nerve terminals. An in vitro study under conditions that mimic anoxia, hypoglycemia, and ischemia. Stroke 27: 941-950, 1996.
77. Sattler R, Xiong Z, Lu WY, Hafner M, MacDonald JF, and Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284: 1845-1848, 1999.
78. Sauer D, Allegrini PR, Cosenti A, Pataki A, Amacker H, and Fagg GE. Characterization of the cerebroprotective efficacy of the competitive NMDA receptor antagonist CGP40116 in a rat model of focal cerebral ischemia: an in vivo magnetic resonance imaging study. J Cereb Blood Flow Metab 13: 595-602, 1993.
79. Saver JL. Time is brain-quantified. Stroke 37: 263-266, 2006.
80. Schell RM, Kern FH, Greeley WJ, Schulman SR, Frasco PE, Croughwell ND, Newman M, and Reves JG. Cerebral blood flow and metabolism during cardiopulmonary bypass. Anesth Analg 76: 849-865, 1993.
81. Shimada N, Graf R, Rosner G, Wakayama A, George CP, and Heiss WD. Ischemic flow threshold for extracellular glutamate increase in cat cortex. J Cereb Blood Flow Metab 9: 603-606, 1989.
82. Shimizu-Sasamata M, Kano T, Rogowska J, Wolf GL, Moskowitz MA, and Lo EH. YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats. Stroke 29: 2141-2148, 1998.
83. Simon R and Shiraishi K. N-methyl-d-aspartate antagonist reduces stroke size and regional glucose metabolism. Ann Neurol 27: 606-611, 1990.
84. Sladeczek F, Pin JP, Recasens M, Bockaert J, and Weiss S. Glutamate stimulates inositol phosphate formation in striatal neurones. Nature 317: 717-719, 1985.
85. Soria FN, Perez-Samartin A, Martin A, Gona KB, Llop J, Szczupak B, Chara JC, Matute C, and Domercq M. Extrasynaptic glutamate release through cystine/glutamate antiporter contributes to ischemic damage. J Clin Invest 124: 3645-3655, 2014.
86. Stern JR, Eggleston LV, Hems R, and Krebs HA. Accumulation of glutamic acid in isolated brain tissue. Biochem J 44: 410-418, 1949.
87. Suzuki Y, Takagi Y, Nakamura R, Hashimoto K, and Umemura K. Ability of NMDA and non-NMDA receptor antagonists to inhibit cerebral ischemic damage in aged rats. Brain Res 964: 116-120, 2003.
88. Swan JH and Leach MJ. Evaluation of the novel neuroprotective agent BW619C89 in the middle cerebral artery occlusion model of focal ischemia in the spontaneously hypertensive rat and normotensive Fischer 344 rat. Ann N Y Acad Sci 765: 39-46; discussion 59-61, 1995.
89. Szydlowska K and Tymianski M. Calcium, ischemia and excitotoxicity. Cell calcium 47: 122-129, 2010.
90. Takahashi M, Ni JW, Kawasaki-Yatsugi S, Toya T, Ichiki C, Yatsugi SI, KoshiyaK, Shimizu-SasamataM, and Yamaguchi T. Neuroprotective efficacy of YM872, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanentmiddle cerebral artery occlusion in rats. J Pharmacol Exp Ther 287: 559-566, 1998.
91. Takizawa S, Hogan M, and Hakim AM. The effects of a competitive NMDA receptor antagonist (CGS-19755) on cerebral blood flow and pH in focal ischemia. J Cereb Blood Flow Metab 11: 786-793, 1991.
92. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M, and Wada K. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276: 1699-1702, 1997.
93. van den Berg CJ and Garfinkel D. A stimulation study of brain compartments. Metabolism of glutamate and related substances in mouse brain. Biochem J 123: 211-218, 1971.
94. Vilchez D, Ros S, Cifuentes D, Pujadas L, Valles J, Garcia-Fojeda B, Criado-Garcia O, Fernandez-Sanchez E, Medrano-Fernandez I, Dominguez J, Garcia-Rocha M, Soriano E, Rodriguez de Cordoba S, and Guinovart JJ. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 10: 1407-1413, 2007.
95. Wahl F, Obrenovitch TP, Hardy AM, Plotkine M, Boulu R, and Symon L. Extracellular glutamate during focal cerebral ischaemia in rats: time course and calcium dependency. J Neurochem 63: 1003-1011, 1994.
96. Weller ML, Stone IM, Goss A, Rau T, Rova C, and Poulsen DJ. Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuroprotection from moderate but not severe hypoxiaischemia. Neuroscience 155: 1204-1211, 2008.
97. Worby CA, Gentry MS, and Dixon JE. Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J Biol Chem 283: 4069-4076, 2008.
98. Xing C, Arai K, Lo EH, and Hommel M. Pathophysiologic cascades in ischemic stroke. Int J Stroke 7: 378-385, 2012.
99. Xue D, Huang ZG, Barnes K, Lesiuk HJ, Smith KE, and Buchan AM. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J Cereb Blood Flow Metab 14: 251-261, 1994.